Frontera Therapeutics is an AAV gene therapy company with the mission to establish a low-cost and scalable platform, to develop and produce high-quality and affordably priced rAAV therapies for the global market.
Spectrum Medical is a clinical mass spectrometry product platform that promotes clinical mass spectrometry detection technology to the general public. It has an experienced research and development, operations, and sales team, a standardized GMP production workshop, extensive experience in laboratory construction, and a mature laboratory management system. It provides with complete supporting kits in addition to mastering the core mass spectrometry hardware manufacturing technology and equipment integration development capabilities (maternal and child genetics, nutritional levels, therapeutic drug testing, metabolic monitoring, etc.).
ProfoundBio is a clinical-stage biotechnology company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer. Built on internally developed, innovative, and proprietary technology platforms, ProfoundBio has developed a pipeline consisting of multiple antibody-drug conjugate (ADC) drug candidates targeting solid tumors and hematological malignancies that are in discovery, preclinical, and clinical development stages.
Full-Life Technologies is a radiotherapeutics company that provides research and development, production, and commercialization of radiopharmaceuticals for cancer therapy, delivering clinical impact for patients.
Bioforany is a biocatalyst manufacturer specializing in biocatalysts development and sales. Bioforany supply's low-carbon products to consumers in the domains of pharmaceutical intermediates, traditional Chinese medicine decoction components, functional food, animal nutrition, daily chemical care, plant protection, and renewable materials.
Jitai Medicine (METiS) is a biotechnology company that uses artificial intelligence to drive drug delivery and drug discovery. It combines advanced technologies like artificial intelligence, machine learning, and quantum simulation to achieve more effective design of innovative delivery materials, drug candidate selection and formulation design, "programmable nucleic acid drug" development, and nucleic acid delivery design.
Virtue Diagnostics is an innovative IVD company focused on infectious disease, cancer, and chronic diseases.
Jitai Medicine (METiS) is a biotechnology company that uses artificial intelligence to drive drug delivery and drug discovery. It combines advanced technologies like artificial intelligence, machine learning, and quantum simulation to achieve more effective design of innovative delivery materials, drug candidate selection and formulation design, "programmable nucleic acid drug" development, and nucleic acid delivery design.
ABclonal Technology is a rapidly growing life science research and diagnostic reagents provider. With scientists from world-class universities, the company thrives on improving the quality of life science research by providing high-quality antibodies, proteins, ELISA kits, NGS library preparation kits and molecular enzymes.
METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.
BDG is a specialist hospital focusing on the diagnosis and treatment of brain diseases, brain health management, and brain neurology research.
KingstronBio manufactures artificial heart valves and annuloplasty rings.
Kangjing Bio focuses on the research and development of innovative drugs for the immunotherapy of autoimmune diseases and tumors. A round of financing of nearly 100 million yuan has been completed. This round of financing was jointly led by Sequoia China and Yahui Investment, followed by Fuchuang Investment and Renyou Investment. For this transaction, Hejun Capital and Chenrui Capital acted as financial advisors. This round of financing will be mainly used for phase I clinical trials of complement inhibitors under research on new targets, the advancement of other pipeline drugs, and the further consolidation of the application of innovative drug research and development platforms based on the complement system.
Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.
Jianhai Technology is an AI whole-course management platform that provides users with post-hospital & post-diagnosis management services.
Structure Therapeutics creates life-changing medicines for patients using advanced computational and structure-based technology. Our platform combines the latest advancements in computational chemistry, visualization of molecular interactions, and data integration to design orally available, superior medicines that overcome current limitations in biologic and peptide drugs. We are advancing our clinical-stage pipeline of differentiated, efficacious and safe treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic and pulmonary conditions. At Structure, our team’s deep experience with complex biological targets and mechanisms, structure-based drug design, and global drug discovery and development enables our bold vision: to design and develop world-class medicines with tremendous patient impact and broad commercial opportunity.
Vision X is a solutions provider for medical equipment in the field of ophthalmology and optometry.
Geneus develops and commercializes gene sequencers and reagents. The core of its technology is based on the characteristic current signal generated by the interaction of protein nanopores and nucleic acid bases, and it realizes single-molecule nucleic acid sequencing through an integrated chip system.
Cellular Biomedicine Group is a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. It is the result of the acquisition, transfer, commercialization, and advancement of thirty years of research and human treatment experience in cellular medicine. Its cellular research and development is the result of collaboration among scientists and doctors from the US, England, and China.
Yixue Jie is an app that offers medical information to medical workers. They provide information in these categories such as grassroots medical voice in the medical field, medical tumor channel, medical rheumatology and immunity channel, medical skin channel, medical cardiovascular channel, medical endocrinology channel, medical neurology channel, medical blood channel, medical pediatric channel, medical obstetrics and gynecology channel, medical respiratory channel, medical nephrology channel, digestive liver disease channel in medical circles, clinical pharmacy channel of the medical community, medical rare disease channel, medical cancer association, medical emergency and critical care channel, medical spirit channel, medical surgical channel, medical nursing channel, medical ophthalmology channel, medical infection channel, medical anesthesia channel, medical orthopedics channel, medical testing channel, medical image diagnosis and intervention channel, medical pathology channel, clinical decision assistant, a course in the medical field, and medical examination. It helps clinicians in clinical decision-making and professional advancement.
XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform. Through its tightly interwoven quantum mechanics, artificial intelligence, and high-performance cloud computing algorithms, the ID4 platform enables pharmaceutical companies to increase their efficiency, accuracy, and success rate at critical stages of drug R&D. By accelerating the pace of drug discovery and development, XtalPi aims to contribute to a healthier society worldwide. Founded in 2014 by a group of quantum physicists at MIT, XtalPi has since grown into an elite team of researchers with multi-disciplinary expertise in physics, chemistry, pharmaceutical R&D, and algorithm design. XtalPi has received much recognition for its cutting-edge technologies, its innovative solutions, and the breadth of potential applications of its offerings across the pharmaceutical value chain, which has allowed it to gain industry approval and establish strategic partnerships with several top international pharmaceutical companies.
Bota Biosciences (Bota Bio) is a global industrial biotechnology company connecting biological design to scale-up manufacturing to accelerate shifts to sustainable living. Bota has built an integrative bioengineering platform, to develop and implement efficient, eco-friendly, and cost-effective biomanufacturing technologies. Committed to its mission, Bota established its own pilot plant and manufacturing facility, affirming its dedication to offering scalable industrial solutions and market-ready products. This infrastructure strengthens support for customers and partners across industries such as nutrition, food, personal care, and animal health. Powered by a dynamic, multidisciplinary team, Bota Bio channels biotech innovations to create a global impact. The company's Series B financing has surpassed $100 million, bringing its aggregate funding to $145 million, with investment from notable strategic and financial investors, including Hong Shan Capital, Matrix Partners, and BASF Ventures.
ProfoundBio is a clinical-stage biotechnology company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer. Built on internally developed, innovative, and proprietary technology platforms, ProfoundBio has developed a pipeline consisting of multiple antibody-drug conjugate (ADC) drug candidates targeting solid tumors and hematological malignancies that are in discovery, preclinical, and clinical development stages.
Bexion is a software-based species design, biomanufacturing and biotechnology ecological company. Aiming at software-engineered species design - giving full play to the self-replication and scalability of biological software and hardware, establishing a modular genome code base, a rapid iteration platform, and completely unlocking the productivity of the biological industry. Beisheng's products are artificial species libraries and related pipelines that meet specific industrial purposes, focusing on the research and development of food, daily chemicals, and protein drugs.
HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. The company was founded in 2013 and is headquartered in Paris, Ille-de-France.
Analytical Biosciences is a single-cell genome developer that aims to create and apply accurate maps of human diseases. In collaboration with medical research institutions, hospitals, and pharmaceutical companies, we are committed to exploiting the application of single-cell genomics and bioinformatics in the diagnosis and treatment of human diseases. Through large-scale systematic disease single-cell mapping, big data intelligence mining is carried out to help a wide range of partners discover new therapeutic targets and develop new treatment strategies.
Valgen focus on treatment technologies and systemic solutions for heart disease, especially for mitral and tricuspid valve lesions.
EdiGene is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.
Benchling is the modern software platform purpose-built for life science R&D. Hundreds of thousands of scientists using cutting-edge techniques like CRISPR, CAR-T immunotherapy, and genetic engineering depend on our suite of cloud applications to design DNA, collaborate on experiments, manage research workflows, and make critical R&D decisions.
Qihan Biotech is a biomedical company based on genetic technology. Kaixin Bio ’s mission is to create a new world where patients do n’t have to wait for organ transplants. We are committed to using the world's advanced gene editing technology to produce safe and effective cells, tissues and organs that can be used for human transplantation, and to solve the serious shortage of organ transplant donors in China and the world.
Jianhai Technology is an AI whole-course management platform that provides users with post-hospital & post-diagnosis management services.
Neuracle is a well-known enterprise in the field of neuroscience in China. They rely on Tsinghua University's independent innovation and international leading "brain-machine interface" technology, and are committed to innovative research in the fields of neuroscience, psychology, neuroengineering, etc., providing professional and complete solutions for the diagnosis, treatment and rehabilitation of clinical neurological diseases. Program. Their products cover a wide range of fields including clinical medicine, neuroscience, psychology, management marketing, etc., and take the lead in undertaking the National Twelfth Five-Year Science and Technology Support Program. The research and development results and products have been experts in neuroscience and clinical medicine at home and abroad. widely accepted.
ABclonal Technology is a rapidly growing life science research and diagnostic reagents provider. With scientists from world-class universities, the company thrives on improving the quality of life science research by providing high-quality antibodies, proteins, ELISA kits, NGS library preparation kits and molecular enzymes.
Jifan Biotechnology is a biotechnology firm that provides molecular biology reagents, diagnostic raw materials, and kits for research.
VISEN is an innovative biopharmaceutical company focused on endocrine diseases. We are dedicated to providing innovative therapies and compassionate, patient-centric care, because we believe that achieving better treatment processes and outcomes results in living better lives. Putting patients’ need first, VISEN is committed to providing first-in-class or best-in-class products and treatments for endocrine diseases. Our therapeutic areas cover endocrine diseases in adults and children, and rare endocrine diseases. VISEN comprises seasoned professionals with multinational pharmaceutical experiences and leverages cutting-edge technologies and leading resources across the world. We are focused on the Chinese market, and have established offices in Shanghai, Beijing, Hong Kong and Taipei. We have also launched our Greater China R&D and manufacturing site in Suzhou to enhance R&D, manufacturing and commercialization efforts. Our goal is to enable Chinese endocrine patients to benefit from the world's most advanced and reliable treatment solutions earlier.
Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.
Insight Lifetech is a medical technology company dedicated to the development of innovative solutions that have the potential to transform the precision diagnosis and treatment of cardiovascular diseases. It has created a synergistic platform that seamlessly integrates its R&D, manufacturing, and commercialization capabilities, enhancing collaboration across functions, speeding up product development, achieving cost-efficiency, and promoting innovation. It created the first and only domestic fractional flow reserve (FFR) system in China that was approved by the NMPA.
dMed is a full-service Clinical Contract Research Organization that provides industry solutions to pharma and medical device companies. Its business covers consulting, regulatory affairs & strategy, early clinical development, clinical science & medical affairs, clinical operations, biostatistics & programming, data management, drug safety & pharmacovigilance, quality assurance, and information solutions. dMed has set up offices in major cities, including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels, and it employs around 600 professionals globally, among them 60% holds master above degree and 25% with more than 10 years working experiences.
METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.
D3 Bio is a biotechnology company that focuses on discovering and creating medications in oncology and immunology. The company combines clinical and market data to identify shortcomings in existing conventional medicines, employs unique drug development methodologies aimed at new disease targets and delivery routes, and provides patients with therapy alternatives in immunology and oncology.
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions.
EdiGene is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.
XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform. Through its tightly interwoven quantum mechanics, artificial intelligence, and high-performance cloud computing algorithms, the ID4 platform enables pharmaceutical companies to increase their efficiency, accuracy, and success rate at critical stages of drug R&D. By accelerating the pace of drug discovery and development, XtalPi aims to contribute to a healthier society worldwide. Founded in 2014 by a group of quantum physicists at MIT, XtalPi has since grown into an elite team of researchers with multi-disciplinary expertise in physics, chemistry, pharmaceutical R&D, and algorithm design. XtalPi has received much recognition for its cutting-edge technologies, its innovative solutions, and the breadth of potential applications of its offerings across the pharmaceutical value chain, which has allowed it to gain industry approval and establish strategic partnerships with several top international pharmaceutical companies.
JW Therapeutics is a developer of cell-based therapy technologies created to revolutionize cancer treatment.The company focuses on development, transformation and promotion of cell-based immunotherapies that uses chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to regulate the body's immune system, enabling doctors to save the lives of cancer patients and improve the quality of life.
Atom Bioscience is a clinical-stage biotechnology company developing new treatments for inflammatory and metabolic diseases such as chronic gout and non-alcoholic steatohepatitis.
BuyMed operates an e-commerce website that connects pharmaceutical manufacturers, distributors, and clinics. Its platform, Thuocsi.vn, works on a variety of projects, including e-commerce, seller centers, supply portals, WMS, POS, and logistics services. It has been implementing the Circa pharmacy project, focusing more on patient customers.
CERo Therapeutics, Inc. is a new cellular immunotherapy company. We have created a hybrid platform that integrates innate and adaptive programs to eliminate disease.
Qure AI is a healthtech startup that uses artificial intelligence assistance for medical imaging diagnostics. The company's mission is to make healthcare affordable and accessible using the power of artificial intelligence. They build deep learning solutions that aid physicians with routine diagnosis and treatment, allowing them to spend more time with patients. Qure AI was founded in 2016 and is based in Mumbai, Maharashtra.
Transcenta is a global biotherapeutic company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacture, focusing on developing innovative antibodies to help more patients. HJB and MabSpace Biosciences merged and created Transcenta.
RootPath is a Cambridge-based biotechnology company developing a powerful personalized T cell therapy platform that bridges precision medicine and cancer immunotherapy. Their next generation technologies allow us to precisely monitor, modulate and steer the immune system for a revolution in the diagnosis and treatment of cancer.
Qihan Biotech is a biomedical company based on genetic technology. Kaixin Bio ’s mission is to create a new world where patients do n’t have to wait for organ transplants. We are committed to using the world's advanced gene editing technology to produce safe and effective cells, tissues and organs that can be used for human transplantation, and to solve the serious shortage of organ transplant donors in China and the world.
Founded in 2015, Vim connects data to workflow at health care’s “last mile”: within clinical operations at the point of patient care. Health plans, patients, and medical providers of every size – from independent practitioners to integrated delivery systems – use Vim software to connect data and care across the health system. Vim’s mission is to power affordable, high quality health care through seamless connectivity. For more information, please visit getvim.com.
HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. The company was founded in 2013 and is headquartered in Paris, Ille-de-France.
Yaoyanshe is a CRO technology platform. They provide CRO services such as clinical monitoring, project management, registration affairs, biostatistics, pharmacovigilance, and medical affairs. They also provide SMO services. Yaoyanshe addresses the industry's most pressing issues and advances the objective of more effective pharmaceutical research and development.
Yuanxin Huibao is a health insurance technology service provider. It provides insurance for health care in major areas such as major diseases and chronic diseases. It provides users with more reliable medical and medical services and is more insurance. The company offers solutions such as “product actuarial pricing, risk control, user acquisition and viscosity”.
Biofourmis is a biotechnology company that augments personalized care and therapies using digital therapeutics. The company discovers, develops, and delivers clinically validated software-based therapeutics to enable better outcomes for patients. These solutions include advanced tools for clinicians to deliver personalized care and cost-effective solutions for payers. Biofourmis was founded in 2015 and headquartered in Boston, Massachusetts.
Tencent Trusted Doctors, a company established in early August 2018 upon the merger of Tencent Doctorwork and Trusted Doctors, is acquiring the start-up in an attempt to create a private healthcare network that provides both online and offline services through the so-called "celebrity effect".
Burning Rock focuses on providing individualized cancer treatment guidance for the patients. Using medical and bio informatics plus Next-Generation Sequencing (NGS) as the core technologies, the company is committed to offering one-stop solution for clinical and R&D services concerning the genetic testing of individualized cancer treatment. Established in March 2014, Burning Rock is headquartered in Beijing. Its first medical laboratory, "Guangzhou Burning Rock Medical Examination Institute Co., Ltd." is situated on Guangzhou International Bio Island which is blessed with a picturesque environment and rich in scientific research deposits. Later it established a R&D center in Shanghai. It occupies over 10,000 ㎡ in total. Burning Rock is committed to guiding the individualistic treatment of tumor patients, centered around NGS and biomedical informatics, with conventional tumor molecular pathology detection as the cornerstone, trying to build one-stop solutions for individualistic treatment clinical detection service and scientific research of tumor.
BrightGene Bio-medical technology Co.,Ltd., is a leading Chinese biopharmaceutical company in small molecules and nucleotide drugs areas. Advised by China-based venture capital fund Laurel Venture Capital, BrightGene invests in all stage therapeutics and innovations.
Transcenta is a global biotherapeutic company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacture, focusing on developing innovative antibodies to help more patients. HJB and MabSpace Biosciences merged and created Transcenta.
VoxelCloud provides automated medical image analysis services and diagnosis assistance based on AI and cloud computing technologies. The company provides to clinical practices and practitioners automated medical image analytics and diagnostics services based on artificial intelligence and cloud computing technologies. VoxelCloud's proprietary algorithms offer accurate, accessible, and personalized medical image analysis through deep learning and related AI techniques. The company's current products cover lung cancer, retinal diseases, and coronary heart disease. VoxelCloud also has offices in Shanghai and Suzhou in China, as well as a satellite R&D team in Phoenix. The company was founded in Los Angeles in 2016.
Xiaoyaoyao is a comprehensive pharmaceutical circulation field in the era of big data and the Internet As a service provider. Xiaoyaoyao's "Pharmaceutical Help" platform is an e-commerce platform that has been approved by the State Food and Drug Administration and has a B2B drug wholesale license, integrating drug procurement, warehousing, sales, logistics and distribution. , subverting the traditional procurement model of hierarchical distribution. At present, the business has covered more than 20 provinces across the country, with a storage area of nearly 500,000 square meters, serving more than 3,000 suppliers and more than 500,000 pharmacies and clinic end customers across the country.
Deep Intelligent Pharma (DIP) is a global start-up dedicated to empowering and accelerating drug discovery, development and registration through the most advanced AI technologies. With our end-to-end AI-driven platforms, we enable clients to efficiently move compounds from the lab to post-marketing stage with great quality. DIP's core team comes from top Internet companies and pharmaceutical MNCs. Our business operates across China, United States and Japan with global view starting from Day 1.
RootPath is a Cambridge-based biotechnology company developing a powerful personalized T cell therapy platform that bridges precision medicine and cancer immunotherapy. Their next generation technologies allow us to precisely monitor, modulate and steer the immune system for a revolution in the diagnosis and treatment of cancer.
Qihan Biotech is a biomedical company based on genetic technology. Kaixin Bio ’s mission is to create a new world where patients do n’t have to wait for organ transplants. We are committed to using the world's advanced gene editing technology to produce safe and effective cells, tissues and organs that can be used for human transplantation, and to solve the serious shortage of organ transplant donors in China and the world.
Eden Biologics, formerly known as JHL Biotech ("JHL") , is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners through the provision of contract development and manufacturing services. We are specialists in manufacturing biologics, from cell line development to commercial manufacturing with both global and regional regulatory affairs expertise.
Brii Biosciences is a developer of bio-pharmaceutical medicines intended to provide medical solutions to Chinese patients to fulfill their health and treatment needs. The company's medicines focuses on infectious disease drug development and commercialization in China and leverage technology and data to drive improvements to the Chinese healthcare system and outcomes for patients, enabling patients to get access to better treatments and cures for life-threatening diseases.
Grail develops a pan-cancer screening test designed to detect cancers at an early stage. Its pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection. The company was founded in 2016 by Alex Aravanis and Jeff Huber in Menlo Park, California.
HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. The company was founded in 2013 and is headquartered in Paris, Ille-de-France.
MabSpace Biosciences, is a biotech company focused on discovery and development of innovative antibody based therapeutics for cancer and fibrotic diseases. It was founded in 2013 by indrustrial veterans and is located in Biobay Suzhou, an emerging bitech incubator in China. MabSpace employes its proprietary platform technology, immune tolerance breaking technology (IMBT), to generate lead antibodies with diverse epitopes. MabSpace has established multiple antibody discovery and co-development partnerships based on this technology. MabSpace raised 15 million USD from Lilly Asia Ventures in 2015 to advance its lead antibody program, a potentially best-in-class anti-PD-L1 antibody with unique pH-dependent binding and recycling property and significantly improved efficacy in animal models. It has also built a panel of 2nd generation immuno-oncology antibodies targeting different components of the tumor microenvironment,which enables the testing of combination therapeutic interventions with its PD-L1 antibody.
JW Therapeutics is a developer of cell-based therapy technologies created to revolutionize cancer treatment.The company focuses on development, transformation and promotion of cell-based immunotherapies that uses chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to regulate the body's immune system, enabling doctors to save the lives of cancer patients and improve the quality of life.
Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies inside patient cells. Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology. Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck.
Hitales provides research and development services on natural language processing technology and the transformation and application of artificial intelligence technology in the medical field to make medical treatment. They analyze and replicate the scarce medical capabilities of tertiary hospitals through technical means and apply them. It offers intelligent diagnosis and treatment, medical academic research, and national health.
MedGenome is a developer of sequencing genomics-based diagnostics and research platform intended to improve global health. The company's platform applies genomics technologies, bioinformatics, computing, and big data analytics to the genetically diverse and large population to understand the genetic basis of cancer, metabolic disorders, eye disorders, and other rare diseases, enabling the healthcare industry to develop deep insights into diseases at the genetic and molecular level.
Practo is the trusted and familiar home where they know they’ll find a healing touch. It connects them with everything they need to take good care of themselves and their family - assessing health issues, finding the right doctor, booking diagnostic tests, obtaining medicines, storing health records or learning new ways to live healthier. Healthcare providers can also harness the power of Practo as the definitive platform that helps them build their presence, grow establishments and engage patients more deeply than ever.
Innovaccer offers a Healthcare Intelligence Cloud that transforms fragmented healthcare data into actionable insights, enhancing patient care and operational efficiency. The platform supports value-based care initiatives by integrating various functionalities such as risk adjustment, population health management, and omnichannel marketing.
Health 724 is a health service provider based on users, health managers, and health products. They offer direct supply of health products to users who are concerned about their own and their families' health, as well as customized health solutions.
Zai Lab is an innovative biopharmaceutical company based in Shanghai focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Since their founding in 2014, their experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. They see theirselves as the trusted partner of choice for global biopharmaceutical companies seeking to access the Chinese market. Leveraging their team’s extensive global drug development expertise, combined with their demonstrated understanding of the pharmaceutical industry, the increasingly favorable clinical and regulatory environment in China and their in-house manufacturing capabilities, they plan to continue to secure relationships with global pharmaceutical companies to further expand their pipeline and foster innovation in China. Their team is passionate about bringing transformative new medicines to patients. Their vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing their partner’s and their own products in China and around the world. To that end, they have built manufacturing capabilities to support the clinical and commercial production of their drug candidates in China, and they expect to have further clinical production capabilities in the near future. Their team is planning to establish a specialized commercial team to support marketing of their products in China and beyond, and they are expanding their discovery efforts both internally and through collaborations with leading academic institutions.
Life Infinity is a health management company that offers age-specific diagnosis and treatment, as well as the prevention of related diseases. It also offers systematic management of chronic diseases, ageing delay, symptom relief, major disease prevention, and more.
Baheal Pharmaceutical Group is a pharmaceutical commercialization platform. They also provide health brand marketing promotion, pharmaceutical wholesale distribution, and retail services.
Life Infinity is a health management company that offers age-specific diagnosis and treatment, as well as the prevention of related diseases. It also offers systematic management of chronic diseases, ageing delay, symptom relief, major disease prevention, and more.
Burning Rock focuses on providing individualized cancer treatment guidance for the patients. Using medical and bio informatics plus Next-Generation Sequencing (NGS) as the core technologies, the company is committed to offering one-stop solution for clinical and R&D services concerning the genetic testing of individualized cancer treatment. Established in March 2014, Burning Rock is headquartered in Beijing. Its first medical laboratory, "Guangzhou Burning Rock Medical Examination Institute Co., Ltd." is situated on Guangzhou International Bio Island which is blessed with a picturesque environment and rich in scientific research deposits. Later it established a R&D center in Shanghai. It occupies over 10,000 ㎡ in total. Burning Rock is committed to guiding the individualistic treatment of tumor patients, centered around NGS and biomedical informatics, with conventional tumor molecular pathology detection as the cornerstone, trying to build one-stop solutions for individualistic treatment clinical detection service and scientific research of tumor.
OMMAY provides children and family medical care and healthcare services.
Zai Lab is an innovative biopharmaceutical company based in Shanghai focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Since their founding in 2014, their experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. They see theirselves as the trusted partner of choice for global biopharmaceutical companies seeking to access the Chinese market. Leveraging their team’s extensive global drug development expertise, combined with their demonstrated understanding of the pharmaceutical industry, the increasingly favorable clinical and regulatory environment in China and their in-house manufacturing capabilities, they plan to continue to secure relationships with global pharmaceutical companies to further expand their pipeline and foster innovation in China. Their team is passionate about bringing transformative new medicines to patients. Their vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing their partner’s and their own products in China and around the world. To that end, they have built manufacturing capabilities to support the clinical and commercial production of their drug candidates in China, and they expect to have further clinical production capabilities in the near future. Their team is planning to establish a specialized commercial team to support marketing of their products in China and beyond, and they are expanding their discovery efforts both internally and through collaborations with leading academic institutions.
Practo is the trusted and familiar home where they know they’ll find a healing touch. It connects them with everything they need to take good care of themselves and their family - assessing health issues, finding the right doctor, booking diagnostic tests, obtaining medicines, storing health records or learning new ways to live healthier. Healthcare providers can also harness the power of Practo as the definitive platform that helps them build their presence, grow establishments and engage patients more deeply than ever.
Zai Lab is an innovative biopharmaceutical company based in Shanghai focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Since their founding in 2014, their experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. They see theirselves as the trusted partner of choice for global biopharmaceutical companies seeking to access the Chinese market. Leveraging their team’s extensive global drug development expertise, combined with their demonstrated understanding of the pharmaceutical industry, the increasingly favorable clinical and regulatory environment in China and their in-house manufacturing capabilities, they plan to continue to secure relationships with global pharmaceutical companies to further expand their pipeline and foster innovation in China. Their team is passionate about bringing transformative new medicines to patients. Their vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing their partner’s and their own products in China and around the world. To that end, they have built manufacturing capabilities to support the clinical and commercial production of their drug candidates in China, and they expect to have further clinical production capabilities in the near future. Their team is planning to establish a specialized commercial team to support marketing of their products in China and beyond, and they are expanding their discovery efforts both internally and through collaborations with leading academic institutions.